Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
French
German
Italian
Japanese
Portuguese (Brazilian)
Spanish

Clinical Study Results

  • LISALGIL ® - Stroke
    Clinical Study Number 1093.15
    Study Indication Stroke
    Product LISALGIL ®
    Generic Name Metamizole
    Lab Code
    Clinical Phase IV
    Study Title

    A randomized, multicentre, double-blind clinical trial of Metamizole 2g /8 h, i.v. ampoules, versus Placebo every 8 h, i.v. ampoules, administered during 3 days consecutively as antithermic therapy in the acute phase of ischemic stroke. A 30-day study. (ATIS Study)

    Study Document
    Trial synopsis 1093.15 english
  • LISALGIL ® - Migraine Disorders
    Clinical Study Number 1093.16
    Study Indication Migraine Disorders
    Product LISALGIL ®
    Generic Name Metamizole
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, double blind, placebo- and active-controlled parallel group study investigating the efficacy and tolerability of metamizol 0.5 g and 1.0 g in patients with episodic moderate tension headache.

    Study Document
    Trial synopsis 1093.16 english
  • LISALGIL ® - Pain
    Clinical Study Number 1093.18
    Study Indication Pain
    Product LISALGIL ®
    Generic Name Metamizole
    Lab Code
    Clinical Phase IV
    Study Title

    Randomized, double blind, comparative trial of the efficacy and tolerability of Nolotil  i.v. vs. Placebo i.v. in the prevention of postoperative pain in children of 6 and 11 years old undergoing minor surgery

    Study Document
    Trial synopsis 1093.18 english